Dr. Daniel Grosu is the Founder and Managing Partner of GenoPraxis, LLC – a San Diego based specialty consultancy dedicated to enabling the practical implementation of genomic testing technologies. He is also an active angel investor, and sits on the Life Science committee of Tech Coast Angels (San Diego). Dr. Grosu previously served as Sequenom’s last Chief Medical Officer (until the company’s acquisition by LabCorp) and as Illumina’s first Chief Medical Officer. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE Marking of the MiSeqDx platform and associated cystic fibrosis assay – the world’s first NGS-based in-vitro diagnostic (IVD) product. Earlier in his career, Dr. Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.